Concerns Rise over Peptide Safety in the Beauty-Meets-Wellness Industry
The beauty and wellness industry has expanded significantly, reaching a combined worth of $6.8 trillion. However, concerns have emerged regarding the safety of peptides, a popular component in products ranging from injections to lip balms.
Researchers at Northeastern University have raised alarms about the rapid use of peptides without a strong track record for safety and effectiveness. Their concerns follow a recent meeting by the U.S. Food and Drug Administration (FDA) addressing the future of certain peptide compounds. Robert F. Kennedy Jr., holding significant influence as the Secretary of the Department of Health and Human Services, has supported this initiative.
Pharmaceutical experts are now questioning whether peptides are ready for mainstream usage. Marketed as solutions for wrinkles and weight reduction by interacting with cell receptors, the effectiveness of these products is under scrutiny.
Peptides and the Biohacking Craze
Peptides have become a focal point in personal care discussions, outpacing other trends like NAD infusions and DNA-coded skincare. In January, U.S. searches for peptides surged to 10.1 million monthly, a significant increase since 2020. Notably, around one in eight Americans are using GLP-1 drugs, known through brands like Ozempic and Mounjaro, which are among the few FDA-approved peptides.
The FDA’s Pharmacy Compounding Advisory Committee met on July 23 to consider expanding access to previously banned peptides, focusing on creating customized medications through specialized pharmacies. Emily G. Hilliard, an HHS press secretary, commented that the FDA will evaluate evidence on peptide benefits and risks to develop a proposed rule.
Earlier this year, Kennedy Jr. suggested that many banned peptides might be re-evaluated for market entry, representing a significant shift in the U.S. regulation landscape.
Expert Opinions
Valerie Aparovich, a biochemist with OnSkin, expressed optimism about the safety of topical peptides like Matrixyl and Argireline. However, she noted that much research stems from companies marketing these ingredients.
Concerns from the Academic Community
Despite the optimism, rare cases of adverse reactions have occurred. In 2025, two women became critically ill following peptide injections at a festival in Las Vegas. Karthik Achari, founder of PepMD, highlighted a gap in regulations, stating that anecdotal evidence exists but controlled data is lacking.
Dr. Neil Panchal of Longevitix emphasized that a regulated pathway is safer than unverified sources. Mansoor Amiji from Northeastern University argued that, apart from a few FDA-approved peptides, comprehensive safety studies are lacking. He warned of possible systemic absorption risks, countering claims of peptides promoting recovery and performance.
Steve Kates, a colleague of Amiji, stated the manufacturing and efficacy standards for these products have not been met, complicating large-scale production.